ici-195739 and Coccidioidomycosis

ici-195739 has been researched along with Coccidioidomycosis* in 1 studies

Other Studies

1 other study(ies) available for ici-195739 and Coccidioidomycosis

Article	Year
Utility of the triazole D0870 in the treatment of experimental systemic coccidioidomycosis. Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology, 1994, Volume: 32, Issue:4 The new triazole, D0870, was tested for therapeutic efficacy in the treatment of experimental systemic murine coccidioidomycosis. D0870 at 1 or 10 mg kg-1 daily, or 10 or 100 mg kg-1 every other day, and fluconazole at 100 mg kg-1 daily prolonged survival (P < 0.01), but were equivalent to each other. D0870 at 10 mg kg-1 daily or 100 mg kg-1 every other day cured 20 or 30% of mice of residual infection, respectively, and were superior to 100 mg kg-1 of fluconazole daily (P < 0.001). D0870 is approximately 10-fold more active than fluconazole. It is a promising treatment for coccidioidomycosis, which warrants further testing. Topics: Animals; Antifungal Agents; Coccidioides; Coccidioidomycosis; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluconazole; Liver; Lung; Mice; Mice, Inbred Strains; Spleen; Stereoisomerism; Triazoles	1994

Article

Year

Utility of the triazole D0870 in the treatment of experimental systemic coccidioidomycosis.

Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology, 1994, Volume: 32, Issue:4

The new triazole, D0870, was tested for therapeutic efficacy in the treatment of experimental systemic murine coccidioidomycosis. D0870 at 1 or 10 mg kg-1 daily, or 10 or 100 mg kg-1 every other day, and fluconazole at 100 mg kg-1 daily prolonged survival (P < 0.01), but were equivalent to each other. D0870 at 10 mg kg-1 daily or 100 mg kg-1 every other day cured 20 or 30% of mice of residual infection, respectively, and were superior to 100 mg kg-1 of fluconazole daily (P < 0.001). D0870 is approximately 10-fold more active than fluconazole. It is a promising treatment for coccidioidomycosis, which warrants further testing.

Topics: Animals; Antifungal Agents; Coccidioides; Coccidioidomycosis; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluconazole; Liver; Lung; Mice; Mice, Inbred Strains; Spleen; Stereoisomerism; Triazoles

1994